In a cohort of 85 patients with biomechanical recurrence of prostate cancer and PSA values less than 2 ng/mL, positive findings on PET imaging with PSMA-18F DCFPyL led to treatment changes in the majority of patients who had negative findings on conventional imaging, according to new research presented at the SNMMI conference.
Emphasizing enhanced time-of-flight performance and an energy-efficient design, the Biograph Trinion PET/CT system can reportedly be utilized for a variety of imaging needs, ranging from theranostic applications to neurology imaging.
In a recent interview, Cathy Cutler, Ph.D., shared her perspective on a number of topics affecting nuclear medicine, ranging from isotope availability and reimbursement challenges for diagnostic radiopharmaceuticals to increasing patient interest in PET imaging.
For patients with interstitial lung disease, FAPI PET/CT was more effective than 18F-FDG PET/CT at predicting progressive pulmonary fibrosis according to comparative study findings presented at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting.
The use of 90Y-FAPI-46 radioligand therapy resulted in controlled disease progression in nearly half of a 30-person cohort largely comprised of patients with advanced sarcomas, according to new research presented at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting.
In addition to new advances in PET/CT imaging to facilitate precision imaging, the company will also unveil a device at the SNMMI conference that allows in-house production of commercial PET tracers.
Catch up on the top radiology content of the past week.
PSMA PET/CT demonstrated an 83 percent pooled detection rate for primary or metastatic renal cell carcinoma (RCC), and an 87 percent detection rate for restaging of metastatic or recurrent RCC, according to a nine-study meta-analysis.
New prospective research examining the utility of 18F-PSMA-1007 PET/CT revealed comparable sensitivity to mpMRI for detecting clinically significant prostate cancer and a 17 percent higher specificity rate.
Catch up on the top radiology content of the past week.
In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.
In a study of women with oligometastatic breast cancer, the use of 18F-FDG PET/CT detected additional metastases in one-third of cases that were not evident on conventional CT.
Catch up on the top radiology content of the past week.
Examining current trends in brain cancer diagnostics, these authors discuss diagnostic imaging advances, pathways with adaptive radiotherapy and the ongoing quest to provide optimal precision with dosimetry.
A recent meta-analysis found that multiparametric MRI and PET/CT had comparable detection rates for diagnosing prostate cancer recurrence.
A positron emission tomography (PET) agent that targets LAT1 and LAT2 membrane transport proteins, TLX101-CDx or 18F-floretyrosine could be utilized to help characterize progressive or recurrent glioma.
Catch up on the top radiology content of the past week.
Utilizing PET imaging to assess pathologic complete response to the combination of trastuzumab and pertuzumab for patients with HER2-positive breast cancer, researchers noted a 94.8 percent rate of invasive disease-free survival at three years.
The multimodality system nCommand Lite reportedly facilitates real-time remote imaging guidance on scanning parameters and procedure assessments to licensed technologists for a variety of imaging modalities including CT and MRI.
Catch up on the top radiology content of the past week.
Ga-PSMA PET MRI offers nearly 22 percent higher sensitivity for localized prostate cancer and comparable specificity to multiparametric MRI, according to a recently published prospective study.
Catch up on the top radiology content of the past week.
For men with PI-RADS 3 lesions, PRIMARY scores of 4-5 with PET/MRI had a sensitivity rate of 87.5 percent for clinically significant prostate cancer, according to newly published research.
Amid new research insights and advances in the management of patients with prostate cancer, Daniel Spratt, M.D., shared his observations in an interview on the emerging role and impact of PSMA-PET imaging.
Catch up on the top radiology content of the past week.
